依普利酮中国的价格

It is a new type of selective aldosterone receptor antagonist. It was approved for clinical use by the State Food and Drug Administration in 2002. The pure product is white or off-white crystal. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

Eplerenone can be used for congestive heart failure after acute myocardial infarction. Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction.

Eplerenone was developed by Pfizer of the United States and was first launched in the United States in 2002. It is mainly used clinically to treat hypertension. In 2003, the FDA approved eplerenone for the treatment of heart failure after acute myocardial infarction. Eplerenone is a new type of selective aldosterone receptor antagonist.

It is understood that eplerenone has not yet been launched in mainland my country, and eplerenone is not available in domestic pharmacies, so eplerenone has not yet been priced in my country. However, there is currently a very popular generic version of eplerenone on the market. Eplerenone from India's Lupine Pharmaceuticals, 50mg*100 tablets, costs around $500 equivalent to RMB. This price is acceptable to most people in China. Patients can contact Medical Companion Travel to purchase the Indian version of eplerenone.

Common side effects include hyperkalemia ([Heart failure, post-myocardial infarction: >5.5meq/L: 16%; ≥6meq/L: 6%, [Hypertension, >5.5meq/L: 400mg: 9%; dose ≤200mg: ≤1%]), hypertriglyceridemia (1%-15%; dose-related).